摘要
目的探讨联合检测血清CA125，CA153，CA199，CA724和CEA含量对卵巢癌的临床诊断价值.方法抽取48例卵巢癌、34例卵巢良性肿瘤患者及30例健康对照者血清，利用罗氏2010全自动电化学发光仪进行CA125，CA153，CA199，CA724和CEA联合检测.结果卵巢癌患者血清CA125，CA153，CA199水平显著高于正常对照组（t分别为3．21，2．78，2．63，均P〈0．05）.卵巢癌患者血清CA125，CA153，CA199阳性率显著高于正常对照组（x^2分别为31．32，15．81，7．04，P〈0．05），阳性率分别为70．8%，43．8%和25．0%.联合检测CA125，CA153，CA199，CA724和CEA诊断卵巢癌的阳性率为83．3%、卵巢良性肿瘤患者的阳性率为29．4%，均显著高于正常对照组（X^2=53．68，8．34，均P〈0．05），且显著高于检测单一肿瘤标志物的阳性率.联合检测的敏感度（83．3%）、准确度（89．7%）均高于单项检测结果.结论联合检测CA125，CA153，CA199，CA724和CEA对于卵巢癌和卵巢良性肿瘤的诊断和鉴别诊断具有重要价值.
Objective To study the significance of combined detection of serum levels of CA125,CA153,CA199,CA724 and CEA in diagnosis of ovarian carcinoma. Methods Serum levels of CA125,CA153,CA199,CA724 and CEA in 48 patients with ovarian carcinoma,34 patients with benign ovarian tumor and 30 healthy women for control were measured by Roche Elecsys 2010 elctrochemilluminescent immunoassay （ECLIA）. Results The serum levels of CA125,CA153 and CA199 in patients with ovarian carcinoma were significantly higher than those in patients with benign ovarian tumor and normal controls （t = 3.21,2.78,2.63,P〈0. 05）. The positive rates of CA125,CA153 and in patients with ovarian carcinoma were 70. 8%,43.8% and 25.0% ,respectively. Their positive rates were significantly higher than those in normal controls （X^2=31. 32,15.81,7.04 ,P〈0. 05）. The positive rates of combined detection of CA125 ,CA153 ,CA199 ,CA724 and CEA in patients of ovarian carcinoma group and benign ovarian tumor were 83.3% and 29.4% respectively. They were significantly higher than normal control and those single tumor marker （Z2=53.68,8.34,P〈0.05）. The sensitivity and accuracy of combined detection of CA125 ,CA153,CA199,CA724 and CEA were 83.3% and 89.3 % respectively. They were significantly higher than single tumor marker. Conclusion The combined detection of CA125,CA153,CA199,CA724 and CEA is valuable for diagnosis of ovarian carcinoma and benign ovarian tumor.
出处
《现代检验医学杂志》
CAS
2009年第2期58-60,共3页
Journal of Modern Laboratory Medicine
